JP2009511014A - 自己免疫疾患の処置のための組成物および方法 - Google Patents

自己免疫疾患の処置のための組成物および方法 Download PDF

Info

Publication number
JP2009511014A
JP2009511014A JP2008534644A JP2008534644A JP2009511014A JP 2009511014 A JP2009511014 A JP 2009511014A JP 2008534644 A JP2008534644 A JP 2008534644A JP 2008534644 A JP2008534644 A JP 2008534644A JP 2009511014 A JP2009511014 A JP 2009511014A
Authority
JP
Japan
Prior art keywords
self
vector
polypeptide
intron
secretory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008534644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511014A5 (https=
Inventor
ナネット ソルベイソン
マイケル レヴィテン
ヒデキ ギャレン
Original Assignee
ベイヒル セラピューティクス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイヒル セラピューティクス インコーポレーティッド filed Critical ベイヒル セラピューティクス インコーポレーティッド
Publication of JP2009511014A publication Critical patent/JP2009511014A/ja
Publication of JP2009511014A5 publication Critical patent/JP2009511014A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008534644A 2005-10-05 2006-10-04 自己免疫疾患の処置のための組成物および方法 Pending JP2009511014A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72420305P 2005-10-05 2005-10-05
PCT/US2006/038776 WO2007044394A2 (en) 2005-10-05 2006-10-04 Compositions and methods for treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
JP2009511014A true JP2009511014A (ja) 2009-03-19
JP2009511014A5 JP2009511014A5 (https=) 2010-12-16

Family

ID=37943343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008534644A Pending JP2009511014A (ja) 2005-10-05 2006-10-04 自己免疫疾患の処置のための組成物および方法

Country Status (9)

Country Link
US (1) US20100160415A1 (https=)
EP (1) EP1931390B1 (https=)
JP (1) JP2009511014A (https=)
CN (1) CN101365494A (https=)
AU (1) AU2006302477A1 (https=)
CA (1) CA2624615A1 (https=)
IL (1) IL190520A0 (https=)
NZ (1) NZ567150A (https=)
WO (1) WO2007044394A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012161352A1 (ja) * 2011-05-25 2012-11-29 国立大学法人岡山大学 Reic発現アデノウイルスベクター
KR101466874B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 자가면역 질환의 예방과 치료를 위한 ｉｌ-６ 수용체에 대한 항체를 발현하는 미니서클
KR101466875B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
JP2021529519A (ja) * 2018-06-25 2021-11-04 アコーオス インコーポレイテッド Ｃｌｒｎ１に関連する聴力喪失及び／または視力喪失を治療する方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1668105T3 (pl) * 2003-09-29 2019-03-29 Deb Ip Limited Kompozycje żelopodobne i pieniące o dużej zawartości alkoholu
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
BRPI0608347A2 (pt) 2005-03-07 2009-12-08 Deb Worldwide Healthcare Inc composição alcoólica espumável, concentrado de composição, composição alcoólica desinfetante espumável, métodos para formar, produzir e dispensar uma espuma, dispensador não pressurizado, e, métodos para usar uma composição alcoólica de espuma para desinfecção pessoal e para produzir e aplicar a uma pele de indivìduo uma composição alcoólica de espuma desinfetante de pele
WO2010151420A1 (en) * 2009-06-05 2010-12-29 Bayhill Therapeutics, Inc. Compositions and methods for treatment of insulin-dependent diabetes mellitus
EP2525825A1 (en) * 2010-01-20 2012-11-28 Bayhill Therapeutics, Inc. Combination therapy to treat autoimmune diseases
US20160287685A1 (en) 2013-11-22 2016-10-06 Amarna Holding B.V. Method for restoring immune tolerance in vivo
EP3090263A4 (en) * 2013-12-31 2017-08-23 Yeda Research and Development Co., Ltd. Methods for assaying immunological competence
US10545144B2 (en) 2013-12-31 2020-01-28 Yeda Research And Development Co., Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
CN106535926B (zh) * 2014-06-04 2022-02-01 戴尔米德医疗公司 用于基于抗原的疗法的新型组合物
US12605432B2 (en) 2014-06-04 2026-04-21 Diamyd Medical Ab Combinations for antigen based therapy
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2017222911A1 (en) * 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
CA3042321A1 (en) 2016-11-01 2018-05-11 Novo Nordisk A/S Tolerogenic dna vaccine
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005510533A (ja) * 2001-11-21 2005-04-21 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ ポリヌクレオチド療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
WO2000002591A1 (en) * 1998-07-09 2000-01-20 Merck & Co., Inc. Polynucleotide vaccine formulations
WO2000046147A2 (en) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
EP1421104A4 (en) * 2001-08-02 2005-08-24 Trinity Biomedical Technology HUMANE ZONA PELLUCIDA PROTEINS AND METHOD FOR THEIR USE IN THE DIAGNOSIS OF MALE INFERENCE
WO2003082269A1 (en) * 2002-03-29 2003-10-09 The Board Of Trustees Of The Leland Stanford Junior University Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
PT1685251E (pt) * 2003-10-10 2014-04-15 Powderject Vaccines Inc Construções de ácido nucleico

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005510533A (ja) * 2001-11-21 2005-04-21 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ ポリヌクレオチド療法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012017390; Ｄｉａｂｅｔｅｓ ｖｏｌ．５１，　ｎｏ．１１, 2002, ｐｐ．３２３７-３２４４ *
JPN6012017392; Ｊ．　Ｉｍｍｕｎｏｌ． ｖｏｌ．１７０，　ｎｏ．４, 2003, ｐｐ．１８０６-１８１３ *
JPN6012017393; Ｐｒｏｍｅｇａ　Ｔｅｃｈｎｉｃａｌ　Ｂｕｌｌｅｔｉｎ：ｐＣＩ　ａｎｄ　ｐＳＩ　Ｍａｍｍａｌｉａｎ　Ｅｘｐｒｅｓｉｏｎ　Ｖｅｃｔｏｒｓ． *
JPN6012017395; Ｐｒｏｍｅｇａ　Ｔｅｃｈｎｉｃａｌ　Ｍａｎｕａｌ：ｐＴＡＲＧＥＴＴＭ　Ｍａｍｍａｌｉａｎ　Ｅｘｐｒｅｓｓｉｏｎ　Ｖｅｃｔｏｒ　Ｓｙｓｔｅｍ． *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012161352A1 (ja) * 2011-05-25 2012-11-29 国立大学法人岡山大学 Reic発現アデノウイルスベクター
JPWO2012161352A1 (ja) * 2011-05-25 2014-07-31 国立大学法人 岡山大学 Ｒｅｉｃ発現アデノウイルスベクター
US9222107B2 (en) 2011-05-25 2015-12-29 National University Corporation Okayama University REIC-expressing adenovirus vector
KR101466874B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 자가면역 질환의 예방과 치료를 위한 ｉｌ-６ 수용체에 대한 항체를 발현하는 미니서클
KR101466875B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
JP2021529519A (ja) * 2018-06-25 2021-11-04 アコーオス インコーポレイテッド Ｃｌｒｎ１に関連する聴力喪失及び／または視力喪失を治療する方法

Also Published As

Publication number Publication date
IL190520A0 (en) 2008-11-03
EP1931390A4 (en) 2009-04-15
US20100160415A1 (en) 2010-06-24
WO2007044394A2 (en) 2007-04-19
CA2624615A1 (en) 2007-04-19
WO2007044394A3 (en) 2007-07-12
CN101365494A (zh) 2009-02-11
EP1931390B1 (en) 2012-07-25
NZ567150A (en) 2011-12-22
AU2006302477A1 (en) 2007-04-19
EP1931390A2 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
US7544669B2 (en) Polynucleotide therapy
JP2009511014A (ja) 自己免疫疾患の処置のための組成物および方法
US20100048679A1 (en) Polynucleotide therapy
US20030229044A1 (en) Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
CN101945666A (zh) 治疗自身免疫和过敏性疾病的组合物及方法
JP4750419B2 (ja) 疾患を予防および治療するための方法および免疫調節核酸組成物
JP2009540016A (ja) 疾患を予防および処置するための方法および免疫調節核酸組成物
JP2003508346A (ja) 自己免疫疾患を治療するためのｄｎａワクチン接種
AU2008201186B2 (en) Polynucleotide therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121121